CPT® Code 87493

Infectious agent detection by nucleic acid (DNA or RNA) for Clostridium difficile involves identifying the presence of specific toxin genes associated with this bacterium. Clostridium difficile, often referred to as C. difficile, is a significant pathogen that can lead to gastrointestinal issues, primarily diarrhea. While many individuals infected with C. difficile experience mild symptoms that may resolve spontaneously or with antibiotic treatment, the bacterium can also produce potent toxins that damage the intestinal lining, potentially resulting in severe conditions such as colitis or even sepsis. The detection process utilizes advanced molecular techniques, specifically an amplified probe technique, which is crucial for identifying the genetic material of the organism. This method is particularly beneficial when the levels of C. difficile in a specimen are low, as traditional direct probe methods may fail to detect the organism. The amplification process involves replicating specific sequences of DNA or RNA, allowing for enhanced sensitivity in the detection of the pathogen. By employing primers—short strands of DNA or RNA that are designed to bind to the target sequences—the polymerase enzyme can create multiple copies of the desired nucleic acid. Following amplification, a laboratory-prepared probe that is complementary to the C. difficile genetic material is used to confirm the presence of the organism. A successful binding of the probe to the specimen indicates a positive result, often signaled by a color change, thus confirming the presence of C. difficile toxin genes in the sample.